Trial Profile
An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary) ; Apomorphine
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Pharma America
- 08 Mar 2024 This study has been Completed in Italy, According to European Clinical Trials Database record.
- 11 Jan 2022 Status changed from recruiting to completed.
- 22 Dec 2021 event This trial has been completed in Austria (Global end date: 11 Aug 2021).